Clinical Trials Directory

Trials / Unknown

UnknownNCT03367559

Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam

An Open Label Study to Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® (Live Attenuated Rotavirus Vaccine) as a 3-dose Series in Healthy Infants Aged Between 6 Weeks and 8 Weeks in Vietnam

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
360 (estimated)
Sponsor
Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products · Academic / Other
Sex
All
Age
6 Weeks – 8 Weeks
Healthy volunteers
Accepted

Summary

An open label study to evaluate immunogenicity, safety, and reactogenicity of Rotavac® (live attenuated oral rotavirus vaccine) as a 3-dose series in healthy infants aged between 6 weeks and 8 weeks in Vietnam.

Conditions

Interventions

TypeNameDescription
BIOLOGICALROTAVAC®Rotavac® is in frozen form and is thawed till fully liquid prior to administration.

Timeline

Start date
2018-02-08
Primary completion
2019-05-01
Completion
2019-05-01
First posted
2017-12-08
Last updated
2019-03-25

Locations

1 site across 1 country: Vietnam

Source: ClinicalTrials.gov record NCT03367559. Inclusion in this directory is not an endorsement.

Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam (NCT03367559) · Clinical Trials Directory